Hi DaveLove your fair, balanced and informative posts.Ive got...

Hi Dave

Love your fair, balanced and informative posts.

Ive got nothing to do. So Im getting excited wishing for more positive info and thinking, why wouldnt you prep for the JP Morgan Health Conference, if not for just a tid bit of info on the MAST study.

You used an analogy of a bile duct patient having gone through the trial and that at day 200 of 350 days his cancer was in remission. Should then day 201 then 202 then 203 etc be reported also? I dont think us punters really want to drill down that far as we have, in summary, the effect of CF33.

However, Leslie answered this question together with another bile duct patient whom was getting treated via IV. Both receiving low dose. Now, I was under the impression that the same time period of 350 days or there abouts was also given. The same positive attributes, were given, yet no data today has been offered on the IV patient. Same as 6 further patients within the gastro cohort with no data shared. Yet. I think that that patient is well beyond the 200 day mark and that there should be some evaluated data to express at the conference

So, I believe once you have the ball rolling, and you gather a bit of moss that you keep the good news forthright and generate interest. Particularly with a stage such as the JP Morgan Health Conference. I mean. It isnt the scientist thats funding IMU.


Source